--> Course PD-L1 as a Biomarker in Immunotherapy in Solid Tumors

PD-L1 as a Biomarker in Immunotherapy in Solid Tumors

Introduction

The immune system is one of the most complex in our body and has evolved through continuous confrontation, fundamentally against pathogenic organisms that are considered external threats to our individuality and integrity. But in addition to defending itself against the threat of foreign substances, it can also defend itself against modified substances from the body itself or against signals that our cells can emit in pathological situations.

In the case of cancer, during its initial development, the immune system monitors and detects the appearance of tumor cells; but in the face of continued and persistent evolution of these abnormal cells, the immune cells become ineffective. This interaction between the immune system and the tumor cell is finely regulated by multiple factors, including the PD-1/PD-L1 axis.

These PD-1/PD-L1 factors are of great clinical interest due to the demonstration that the unblocking of this interaction leads in many cases to the restoration of host immunity against the tumor, and this translates into responses with proven clinical benefit in different types of tumors such as melanoma, lung, kidney and bladder cancer.

Objectives

The selection of which patients benefit from an immunotherapy aimed at modulating the PD-1/PD-L1 interaction is an important clinical question. The study of the expression of PD-L1 as a predictive biomarker by immunohistochemistry has been used for some years in the care practice of various tumors, such as non-small cell lung cancer.

New data from multiple clinical trials based on immunotherapy are extending the use of PD-L1 beyond this type of tumors, based on different immunohistochemical assays or antibodies and on different methods of biomarker assessment.

In addition, the determination of PD-L1 and the results obtained are influenced by many factors such as the pre-analytical conditions of sample processing, the heterogeneity in the expression of the marker in a tumor or the modification of the expression in different evolutions of the disease.

This course aims to deepen the knowledge and understanding of PD-L1 as a predictive biomarker for immunotherapy, the different immunohistochemical assay options and the different interpretation methods for various types of tumors in which these treatments have been shown to be effective.

Who is it for?

This course is aimed at specialist and general pathologists and residents, medical oncologists, biologists and biomedical doctors working in hospitals, and specialists in the pharmaceutical and biotechnology industry.< /p>

 

Open academic periods for enrollment:

- Third Academic Period: From March 1 to May 29, 2022

Event validated with the FENIN Code of Ethics.

MODULE 1
Cancer Immunotherapy
Dr. Luis de la Cruz, Dr. Natalia Palazón Carrión

MODULE 2
PD-L1 as biomarker
Dr. Federico Rojo Todo

MODULE 3
PD-L1 in NSCLC Non-Small Cell Lung Cancer
Dr. Ana Belén Enguita

MODULE 4
PD-L1 in Triple Negative Breast Cancer
Dr. Laura Comerma

MODULE 5
PD-L1 in Urothelial Carcinoma

Dra. Cristina Carrato

MODULE 6
PD-L1 in other tumor types
Dr. Mar Iglesias

Final Evaluation

Satisfaction Survey

FJD
Teaching Hours
11
Price
150 €
Credits
EACCME.
11
eaccme
La actividad con número de registro ELM20-A00112, ha sido acreditada por el Consejo Europeo de Acreditación de Educación Médica Continuada (EACCME) con 11 créditos.
Get the complete information in PDF

Management

Dr. Federico Rojo Todo

Dr. Federico Rojo Todo

Jefe de Servicio de Anatomía Patológica
Fundación Jiménez Díaz, Madrid
Nº de colegiado 280830898
Ilustre Colegio Oficial de Médicos de Madrid
Dr. Luis de la Cruz

Dr. Luis de la Cruz

Director del Servicio de Oncología
H.U. Virgen de la Macarena de Sevilla
Nº de colegiado 4114492
Real e Ilustre Colegio de Médicos de Sevilla

Staff

Dra. Cristina Carrato

Dra. Cristina Carrato

Patóloga
Hospital Germans Trias i Pujol, Barcelona
Nº de colegiada 31549
Col·legi Oficial de Metges de Barcelona
Dra. Laura Comerma

Dra. Laura Comerma

Patóloga
Hospital del Mar-IMIM, Barcelona
Nº de colegiada 42837
Col·legi Oficial de Metges de Barcelona
Dra. Ana Belén Enguita

Dra. Ana Belén Enguita

Especialista en Patología Pulmonar en el Servicio de Anatomía Patológica.
Hospital 12 de Octubre, Madrid
Nº de colegiada 282856909
Ilustre Colegio Oficial de Médicos de Madrid
Dra. Mar Iglesias

Dra. Mar Iglesias

Patóloga
Hospital del Mar-IMIM, Barcelona
Nº de colegiada 34302
Col·legi Oficial de Metges de Barcelona
Dra. Natalia Palazón

Dra. Natalia Palazón

Facultativa Especialista en Oncología
H.U. Virgen de la Macarena, Sevilla
Nº de colegiada 414116721
Real e Ilustre Colegio de Médicos de Sevilla